SHL Telemedicine expands offering in Israel with at-home biomarker blood test

21st May, 2024

Users in Israel will be able for the first time in the world to perform an at-home Biomarker blood test

image credits: shutterstock

image credits: shutterstock

SHL Telemedicine, a leading provider and developer of advanced personal telemedicine solutions, has announced expansion of its at-home Biomarker blood tests in Israel.

This diagnostic tool is designed to rapidly identify cardiac markers for detection of a heart attack, transforming emergency cardiac care with speed and precision. Following concerns of a cardiac event, the addition of the Biomarker test provides a comprehensive snapshot, similar to an emergency room assessment, by combining this novel blood test with a detailed medical history (anamnesis) and a 12-lead ECG transmission. This trio of diagnostic elements, now all available from home with SHL Telemedicine, will aid in identifying cardiac events quickly during the critical symptomatic phase, thus helping save lives.

When a potential cardiac event is suspected, the Biomarker test is administered as the final step in the diagnosis process, following anamnesis and ECG broadcasting. SHL's telemedicine team guides the patient in real-time on how to perform the blood test and continues support until emergency medical services arrive. Results from the Biomarker test are available within ten minutes.

"The ability to perform at-home Biomarker blood tests in Israel is a significant advancement in our mission to revolutionize accessible cardiac care," said Erez Nachtomy, CEO of SHL Telemedicine.

© 2023 MM Activ Sci-Tech Communications. All rights reserved | Disclaimer